J Evid Based Dent Pract by Cleveland, Jennifer L. & Thornton-Evans, Gina
Total Diagnostic Delay in Oral Cancer may be Related to 
Advanced Disease Stage at Diagnosis
Jennifer L. Cleveland, DDS, MPH and
Centers for Disease Control and Prevention, Division of Oral Health, 4770 Buford Highway NE, 
RM 2153, Atlanta, GA 30341, Phone: 770-488-6066
Gina Thornton-Evans, DDS, MPH
Centers for Disease Control and Prevention, Division of Oral Health, 4770 Buford Highway NE, 
RM 2156, Atlanta, GA 30341, Phone: 770-488-5503
Jennifer L. Cleveland: JLCleveland@cdc.gov; Gina Thornton-Evans: GThorntonEvans@cdc.gov
Summary
Selection Criteria
The investigators conducted a systematic search of MEDLINE (1966 to December 2008), 
EMBASE (1974 to 2008), and ISI proceedings (from inception to 2008) for both English 
and non-English articles using a predefined list of search terms. Two clinicians and 1 
epidemiologist independently screened all abstracts to exclude unrelated studies. Only 
articles that presented original data from observational studies were considered. Studies 
were included if they met the following criteria: (1) included patients with confirmed 
pathological diagnosis of oral or oropharyngeal squamous cell carcinoma; (2) the outcome 
of interest was clearly defined as disease stage (TNM classification); (3) the exposure of 
interest was total diagnostic delay defined as the period between the patient noticing either 
the first sign or symptom and definitive diagnosis; and (4) provided relative risks and 95% 
confidence intervals (CIs).
Key Study Factor
Review of studies assessing diagnostic delay in oral cancer. Quality scoring was conducted 
by 2 independent reviewers using the Meta-analysis Of Observational Studies in 
Epidemiology (MOOSE) methodology.1 Three key criteria were assessed: (1) if the follow-
up time was 10 years or longer; (2) if critical confounding factors, such as tobacco and 
alcohol use, were measured; and (3) if results were ascertained by anatomic location of oral 
and pharyngeal cancer. Studies were classified as “yes” or “no” for each of these criteria.
Purpose/Question: To assess whether total diagnostic delay in oral cancer is related to advanced stages of the disease at diagnosis
Type of Study/Design: Systematic review with meta-analysis of data
Level of Evidence: Level 2: Limited–quality patient-oriented evidence
Strength of Recommendation Grade: Grade B: Inconsistent or limited-quality patient-oriented evidence
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The primary outcome was stage at diagnosis (TNM classification).2 The authors classified 
stage at diagnosis in 2 groups: early stage (T1 or T2 and N0) or advanced stage (T3, T4 or N 
> 0). Outcomes of the meta-analysis were expressed as odds ratios (ORs). Two pooled ORs 
were calculated within each key criterion: one for studies that scored “yes” and one for those 
that scored “no”.
Main Results
Nine studies conducted in 9 different countries met the inclusion criteria and were included 
in the analysis. These studies, involving 934 early cases and 961 advanced cases, were 
published between 1989 and 2005.
When compared with the absence of diagnostic delay, patients with diagnostic delay were 
significantly more likely to present at an advanced stage of the disease (fixed effects pooled 
OR 1.32 [95% CI: 1.07-1.62]). The association was stronger when limited to oral versus 
pharyngeal sites (pooled OR 1.47 [95% CI: 1.09-1.99]) and when diagnostic delay was 
longer than 1 month (pooled OR 1.69 [95% CI: 1.26-2.77]). However, the Forest plot 
showed that only pooled fixed effects were significant, not the pooled random effects: only 3 
of the 9 study-specific ORs indicated a significant association.
Conclusions
The analysis estimated that patients with delayed diagnosis had a higher probability of 
presenting with advanced stage oral cancer compared with those without delayed diagnosis, 
particularly among those with oral cancer and those with a delay longer than 1 month. Based 
on the limited quality of the data, however, better evidence about the relationship between 
diagnostic delay and disease progression or disease outcomes is needed.
Commentary and analysis
Stage at diagnosis is an important predictor of survival for patients with oral and pharyngeal 
cancers. Unfortunately, about 60% of these cancers are detected at advanced stages (regional 
or distant) and although improving, 5-year relative survival is poor.3 Regional stage survival 
for 2001 to 2007 was 55% and for distant stage, 33%.3 Therefore, it is important to identify 
strategies to detect these cancers at earlier stages of disease.
This study's objective was to perform a systematic review and meta-analysis to investigate 
whether total diagnostic delay was associated with advanced disease stages.4 Total 
diagnostic delay refers to the period elapsed between the first symptom or sign and the 
definitive diagnosis. There are generally 2 to 3 stages of total diagnostic delay. Patient delay 
refers to the period between when the patient first notices a symptom and the first contact 
with a health care provider. Provider delay is the period between when a patient first 
contacts a health care provider and a specialist's definitive diagnosis. The Gomez study 
included a third stage, scheduling delay, which is the period between the scheduling of the 
appointment and the actual visit to the health care provider. The study had clearly defined 
inclusion criteria, was not limited to the English language, and included both MESH terms 
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and text words. All searches were conducted independently by 2 clinicians and 1 
epidemiologist; however, the steps in the identification of eligible studies was lacking. Nine 
observational studies met the inclusion criteria (randomized controls have not been 
conducted owing to ethical considerations) and differed by period of data collection, 
anatomic site, age range, samples size, and sex. Authors note that the study was limited by 
recall bias and the lack of information on tumor growth rate.
Gomez et al found that the probability for people with delayed diagnosis to present at an 
advance stage of disease was 30% higher than for those without diagnostic de-lay.4 These 
findings are in contrast to a systematic review of 27 studies by Goy et al,5 also published in 
2009, which found no consistent positive association between diagnostic delay in any of the 
head and neck cancer sites analyzed (all head and neck sites combined, oral cavity, pharynx, 
and larynx) and advanced-stage disease. Goy et al5 decided that a quantitative synthesis 
using meta-analysis could not be conducted because of the heterogeneity of the studies. 
Inaccurate measurement of delay, masking of symptoms owing to the effects of smoking or 
alcohol use, recall bias, and variations in the aggressiveness of tumors may have accounted 
for the lack of an observed effect between patient delay and stage.5,6 The latter is an 
important factor because tumor growth rate has been shown to affect stage at diagnosis and 
survival more than diagnostic delay and should be included in studies examining the 
relationship between delay and stage of disease.7,8 Similar to the Goy et al5 study, a recent 
analysis of 88 consecutive patients from 2003 to 2008 also failed to find a relationship 
between diagnostic delay and stage of diagnosis of oral cancer, whereas the site of the 
cancer (floor of the mouth, gingiva, and retromolar area) and degree of differentiation 
(moderate-poor) were significantly associated with high risk of late-stage diagnosis.8 
Because of the heterogeneity of the data and inherent biases, the Gomez et al study and 
others exploring the relationship of delayed diagnosis and stage of disease should be 
interpreted with caution; however, future analyses that include larger numbers of quality 
studies, limit recall bias, and stratify by anatomical site may shed more light on the 
relationship between diagnostic delay and disease stage. These studies also should focus on 
better measurement of delay duration, include tumor growth rate, and relate delay to disease 
outcomes, such as survival and mortality.
Traditionally, visual and tactile screenings as a preventive measure to promote early 
detection and diagnosis of oral cancer lesions are commonly included in cancer control 
programs.9,10 A recent Cochrane review9 concluded, based on one 9-year randomized 
controlled trial with high risk for bias, that there was not enough evidence to support or 
refute the use of visual examination in screening for oral cancer in the general population. 
There was some evidence that visual examination may have helped reduce death rates in 
high-risk patients, such as tobacco and heavy alcohol users.9,10 The American Dental 
Association (ADA) developed clinical recommendations regarding screening for oral 
squamous cell carcinomas during routine examinations, encouraging practitioners to 
“remain alert for signs of potentially malignant lesions or early stage cancers while 
performing routine visual and tactile examinations,” particularly among tobacco and alcohol 
users.11 In addition, neither the Cochrane review nor the ADA recommendations found 
sufficient evidence to recommend adjunctive technologies, such as toluidine blue, 
fluorescence imaging, or brush biopsy in screening for oral cancer.9,11
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This study showed that patients with delayed diagnosis were significantly more likely to 
present with an advanced-stage cancer at diagnosis compared with those with no delay in 
diagnosis. The Healthy People 2020 initiative for the United States includes overall goals to 
reduce health disparities in the general population, which includes individuals at higher risk 
and those who suffer from a greater burden of oral diseases, such as oral and pharyngeal 
cancer.12 These goals include primary and secondary prevention strategies. For example, 3 
developmental objectives focus on screening and counseling patients on tobacco use and 
cessation from the perspective of both the provider and the patient.12 Secondary prevention 
strategies include an objective that focuses on increasing the proportion of oral and 
pharyngeal cancers detected at the earliest stage.12 These objectives validate the role of 
dental practitioners in the primary and secondary prevention of oral cancer through 
screening and counseling patients for tobacco and alcohol use, evaluation that includes 
obtaining a medical history and screening for oral cancer as a component of a thorough head 
and neck examination, especially among patients who use tobacco and alcohol.
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